Regeneron: PCSK9s Drowning In Paperwork
This article was originally published in The Pink Sheet Daily
Executive Summary
But almost 75% of commercially insured patients and 91% of Medicare patients have access to Praluent, the firm reported.
You may also be interested in...
Amgen Plugs Away On Repatha, With Hope For New Monthly Product
In a very strong second-quarter earnings report, Amgen reports just $27m in worldwide sales for cholesterol-busting PCSK9 inhibitor Repatha, as reimbursement continues to present a big hurdle.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.